Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

PVL
Palvella TherapeuticsPVLA
-$15.76M-92.3%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$74.73M-31.5%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$64.17M+15.9%
PTH
Pelthos TherapeuticsPTHS
-$7.05M-258%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.25B-11.7%

Other financials

Income statement

See full
Revenue$129.9M+59.3%
Gross profit$118.9M+60.7%
Operating income$16.4M+212%
Net income$15.0M+194%
EPS (diluted)$0.11+185%

Balance sheet

See full
Cash & equivalents$34.4M-52.9%
Total debt$114.1M+3.6%
Total equity$220.6M+58.7%
Total assets$488.5M+38.6%

Cash flow

See full
Operating cash flow$12.6M
CapEx$158.0K+103%
Free cash flow$12.5M

Valuation

See full
Market cap$3.18B+86.8%
Enterprise value$3.26B+87.4%
P/S6.9×+0.4×

Profitability

See full
Gross margin91.1%+2.0pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.5×-0.3×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001787306-26-000051
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Unrealized gain (loss) on marketable securities(96)(95)(447)(232)
Foreign currency translation adjustment(46)200(165)204
Total other comprehensive income (loss)(142)105(612)(28)
Comprehensive income (loss)$14,867$(15,781)$3,102$(40,974)
Earnings (loss) per share:
Basic$0.11$(0.13)$0.03$(0.32)
Diluted$0.11$(0.13)$0.03$(0.32)
Weighted-average shares used in computing earnings (loss) per share:

Item 1. Financial Statements (Unaudited)

FAQ

What is Arcutis Biotherapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Arcutis Biotherapeutics, Inc. (ARQT) reported comprehensive income (loss), net of tax, attributable to parent of $14.87M in Q2 2026.
How has Arcutis Biotherapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Arcutis Biotherapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent increased by 194.2% year-over-year, from -$15.78M to $14.87M.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Over 3 years (2021 to 2024), Arcutis Biotherapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a -12.2% compound annual growth rate (CAGR), from -$206.61M to -$140.05M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items like unrealized gains or losses on securities. It provides a holistic view of the company's financial performance beyond traditional net income. It is a key indicator for investors to assess the total economic impact of all financial activities on shareholder value.

Ask your AI about Arcutis Biotherapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude